Next Treatments
Back to Eczema

SHR-1819

TypeInjection StagePhase 3 Latest updateUpdated recently. Aug 26, 2026Phase 3 study completed

What stands out

  • Injection every week or 2 weeks in trials
Derived from NCT06012812 · NCT05197023 · This is a summary of public records for informational purposes only. It is not medical advice.

History

Earliest recorded event: Jan 30, 2022. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

  • Aug 26, 2026Phase 3 trial completedEfficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis ClinicalTrials.gov NCT06468956
  • Jun 26, 2026Phase 1 trial completedA Study on the Bioavailability of SHR-1819 Injection Administered Subcutaneously Using Different Injection Devices in Healthy Subjects ClinicalTrials.gov NCT07264335
  • Mar 21, 2026Phase 3 trial startedA Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis ClinicalTrials.gov NCT07309055
  • Mar 7, 2026Phase 1 trial startedA Study on the Bioavailability of SHR-1819 Injection Administered Subcutaneously Using Different Injection Devices in Healthy Subjects ClinicalTrials.gov NCT07264335
  • Jan 9, 2026Phase 2 trial startedA Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis ClinicalTrials.gov NCT07321951
  • Nov 22, 2025Phase 1/2 trial completedA Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis ClinicalTrials.gov NCT06713499
  • Jun 5, 2025Phase 2 trial completedA Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT06012812
  • Dec 18, 2024Phase 1/2 trial startedA Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis ClinicalTrials.gov NCT06713499
  • Jun 14, 2024Phase 3 trial startedEfficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis ClinicalTrials.gov NCT06468956
  • Nov 23, 2023Phase 2 trial completedEfficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis ClinicalTrials.gov NCT05549947
  • Sep 15, 2023Phase 2 main data collectedEfficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis ClinicalTrials.gov NCT05549947
  • Sep 6, 2023Phase 2 trial startedA Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT06012812
  • Oct 27, 2022Phase 1 trial completedA STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS ClinicalTrials.gov NCT05197023
  • Oct 8, 2022Phase 2 trial startedEfficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis ClinicalTrials.gov NCT05549947
  • Jan 30, 2022Phase 1 trial startedA STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS ClinicalTrials.gov NCT05197023

Sources

Trials